Select Page
Responsive Centered YouTube Video
Overview of Rob Malone's journey from retroviruses to mRNA vaccine concept in the late 80s
  • Rob Malone’s fascination with retroviruses led to his exploration of RNA in the late 80s. 1:33

  • Malone’s background in retroviral gene therapy influenced his interest in RNA and mRNA vaccines. 3:14

  • Malone’s initial focus was on understanding how RNA of retroviruses assembles into live virus particles. 4:39

  • RNA serves as a bridge between DNA and proteins in the process of gene expression. 6:20

  • Retroviruses have a unique process involving RNA to DNA conversion, influencing Malone’s research direction. 7:08

Discovery of mRNA vaccine technology through gene therapy experiments and serendipitous non-viral RNA transfer method
  • Initial research on retroviruses packaging RNA to produce viable retroviruses. 7:47

  • Realization of using gene therapy technology to produce vaccines in the 1980s. 9:18

  • Identification of immune response as a challenge in gene therapy and potential solution through vaccine development. 11:03

  • Aha moment regarding the timeline of immune response in mice and gene therapy logic flaw. 11:39

  • Recognition of the need to pivot from gene therapy to vaccine development for practical application. 12:15

Challenges and discoveries in mRNA vaccine research and personal struggles faced by a scientist
  • Research on mRNA in frog embryos led to unexpected success with chick embryos. 13:30

  • Struggles with post-traumatic stress disorder and personal growth during PhD studies. 15:24

  • Transition from Salk Institute to Vical led to significant breakthrough in mRNA research. 17:31

  • Personal experiences and observations of toxic work environment at Salk Institute. 18:48

Challenges faced by a scientist in receiving credit for their contributions in the competitive world of academic research
  • Pressure cooker environment with multiple postdocs assigned to tasks. 20:19

  • Initial excitement and ambition in a prestigious research environment. 21:08

  • Struggle in receiving credit for pioneering work on mRNA vaccines. 22:39

  • Ownership rights and restrictions leading to loss of research opportunities. 23:01

  • Emotional impact likened to feeling of having creation taken away. 24:15

  • Importance of academic recognition and citing intellectual contributions. 25:08

  • Personal commitment to ensure proper credit for all contributions in the academic community. 26:28

Significant advancements in mRNA vaccine technology discussed by Dr. Robert Malone
  • Dr. Malone expresses amazement at the efficiency of mRNA vaccines in gene therapy. 27:38

  • Dr. Peter Cullis and his team played a crucial role in developing lipid formulations for mRNA vaccines. 29:12

  • Despite the benefits, there are potential risks associated with the high efficiency of mRNA vaccines. 30:11

  • Initial focus on drug repurposing over vaccine development during the early stages of the pandemic. 31:20

  • Government decisions to invest in mRNA vaccine technology have been validated. 32:49

  • Dr. Malone provided an independent assessment of data related to mRNA vaccine submissions in Japan. 33:42

Investigation reveals concerning deficiencies in Pfizer vaccine regulatory submission
  • Documents uncovered in Canada raised safety concerns in vaccine recipients. 34:51

  • Scientist requested to review and assess regulatory documents for transparency. 35:50

  • Commitment to openness and transparency in sharing information about experimental products. 37:21

  • Belief in the public’s ability to make informed decisions based on available information. 38:16

  • Challenging scientific community to prevent group think and ensure safety in research. 40:16

  • Independent assessment revealed unusual deficiencies in Pfizer’s regulatory submission. 41:29

Investigation of biodistribution of mRNA vaccine in animal models reveals unexpected spread and concentration in tissues
  • Discovery of unexpected biodistribution of mRNA vaccine in animal models 41:58

  • Use of luciferase RNA in studies to detect protein expression 43:11

  • Presence of injected material in distal sites and biological activity 45:07

  • High concentration of lipids in ovaries compared to testis in rodents 46:21

  • Expectation of injected material to spread through lymphatic system 48:00

  • Formulations engineered to preferentially go through lymphatics to lymph nodes 48:43

Insights on mRNA vaccine distribution and unexpected systemic effects discussed by Robert Malone
  • Systemic distribution of mRNA vaccines was not previously disclosed in literature 49:26

  • Unexpected concentration in organs like ovaries raised concerns 49:49

  • Selection bias in reporting vaccine-related events highlighted 50:10

  • Subjective decisions play a role in determining vaccine-related events 52:34

  • Observation of spike protein spreading systemically in the body discussed 53:12

  • Research on distribution of RNA into cells and spike protein production mentioned 54:44

  • Study involving nurses from Harvard and Brigham on vaccine effects cited 55:29

Insights on spike protein presence in blood, implications on autoimmune response, and scientific approach to hypotheses
  • Detection of free spike protein in nurses’ blood using sophisticated technology 55:50

  • Significant levels of circulating spike protein found in nurses for a prolonged period 56:33

  • Spike protein’s biological activity and potential to bind to ACE2 receptor in vascular endothelial cells 58:10

  • Discussion on triggering autoimmune response post-vaccination and the importance of considering multiple hypotheses in science 1:00:10

  • Adopting a method of multiple working hypotheses in scientific exploration 1:01:18

Discussion on autoimmune response in delayed pathology of COVID-19 and mRNA vaccine safety concerns
  • Immune system responds to foreign protein complexes as different entities 1:02:31

  • Delayed severe COVID-19 disease often linked to autoimmune response 1:03:42

  • Thrombocytopenia and other symptoms consistent with autoimmune functions observed in COVID-19 patients 1:05:11

  • Regulatory agencies require extensive safety data due to autoimmune disease risk 1:06:44

  • Autoimmune diseases manifest over a longer time course, necessitating long-term safety follow-up 1:08:07

  • Urgency to balance vaccine safety with the need to address the current COVID-19 crisis 1:08:50

Concerns raised about the safety of mRNA vaccines, especially in adolescents, due to potential risks like cardiomyopathy
  • Discussion on the appropriateness of continuing mass vaccination, particularly in low-risk groups 1:09:32

  • Concerns raised about safety signals and high levels of spike protein in the blood from mRNA vaccines 1:10:24

  • Importance of full disclosure of risks to patients, especially adolescents who cannot provide full informed consent 1:13:10

  • Identification of safety signal for cardiomyopathy in adolescent population receiving mRNA vaccines 1:14:46

  • Lack of confidence in vaccine safety due to discrepancies in reported data and confirmation of safety signals 1:16:06

Ethical concerns surrounding experimental vaccines and evolving safety databases
  • Government history of tolerating risks in vaccine programs 1:16:46

  • Subjective nature of risk-benefit ratio in vaccine decision-making 1:18:13

  • Importance of informed consent for adolescents receiving experimental vaccines 1:20:03

  • Caution against vaccinating adolescents with evolving safety data 1:21:37

  • Historical ethical dilemmas in public health decision-making 1:22:08

  • Need for rigorous safety data disclosure from other countries 1:23:26

Discussion on ethical concerns and transparency regarding experimental vaccines
  • Importance of full disclosure of risks to patients 1:24:09

  • Need for public comprehension of disclosed risks 1:24:50

  • Belief in individual choice regarding experimental vaccines 1:25:12

  • Acknowledgment of the timeliness and relevance of the discussion 1:25:54

  • Expressing gratitude for the conversation and anticipation of future discussions 1:26:17